Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American C
Magazine Focus
The New Chemistry of Industry: How Chemicals and Pharmaceuticals Are Entering a New Era
Chemicals and pharmaceuticals sit behind an extraordinary range of products, industries and technologies. The sector is now evolving through advances in process engineering, specialty chemistry, pharmaceutical manufacturing, biotechnology, materials science and digital technology. This edition examines the changing landscape across chemicals and pharma, exploring how scientific innovation and modern manufacturing are reshaping the development of molecules, medicines and materials while creating new possibilities across the industries that depend upon them.
Chemistry rarely operates in isolation. Its influence extends from medicines and materials to agriculture, electronics, mobility and everyday consumer products. This edition opens a wider conversation about the transformation taking place across chemicals and pharmaceuticals, examining how science, engineering and manufacturing are converging and why the industry's next phase will increasingly depend on innovation across traditional boundaries.